BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients

Main Article Content

Kenneth Gordon
Kim Papp
Melinda Gooderham
Akimichi Morita
Peter Foley
Diamant Thaçi
Sundeep Kundu
Renata Kisa
Lan Wei
Subhashis Banergee

Keywords

Psoriasis, Tyrosine Kinase Inhibitor

Abstract

Abstract not available.

References

1. Watford WT et al. Immunol Rev. 2004;202:139-156.

2. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

3. Volpe E et al. Nat Immunol. 2008;9:650-657.

4. Geremia A et al. J Exp Med. 2011;208:1127-1133.

5. Tucci M et al. Clin Exp Immunol. 2008;154:247-254.

6. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl10):abstract 11L.

7. Papp K et al. N Engl J Med. 2018;379:1313-1321.

8. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. November 27, 2017. Available at: https://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick Reference_5x7.pdf (accessed January 20, 2020).